Graft rejection is a major problem in bone marrow transplantation for hematologic malignancies. This proposal is based on the observation that the treatment of canine bone marrow recipients with monoclonal antibody S5 from day -7 to day -2 before total body irradiation and transplantation facilitates engraftment of DLA-mismatched marrow. Preliminary data suggest that S5 recognizes a 90kD glycoprotein that may have functional analogy with lymphocyte homing receptors. These human gp90s have been implicated in the adhesion of lymphocytes to high endothelial venules (HEV). For this reason, we have hypothesized that the pretreatment with S5 antibody impairs the host lymphocytes, ability to mediate an immune response against the incoming marrow. The goals of the proposed study include: 1. To more precisely determine the distribution of S5 on functionally distinct bone marrow populations, lymph nodes, and other tissues in the reticuloendothelial system. This will be done on specimens labeled in vitro and on tissue retrieved after in vivo injection. 2. To test the effects of S5 on immune function by: 1) adding the antibody to in vitro assays of lymphocyte function, 2) evaluating the function of cells retrieved from animals after in vivo injection, and 3) testing the effect of S5 on in vivo immune function. 3. To do further structural characterization of the canine gp90 by biochemical and molecular genetic analysis. The candidate is committed to the establishment of a career in academic medicine as a laboratory-based investigator. Fred Hutchinson Cancer Research Center has a unique blend of investigators in both the Clinical and Basic Sciences Divisions with expertise in all aspects of the proposed project along with having the facilities and necessary equipment for the accomplishment of the proposed research. The University of Washington is available for courses pertaining to the field of the proposed field of study.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08CA001483-01
Application #
3079953
Study Section
Cancer Institutional Fellowship Review Committee (CT)
Project Start
1990-07-01
Project End
1995-06-30
Budget Start
1990-07-01
Budget End
1991-06-30
Support Year
1
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Sandmaier, B M; Storb, R; Bennett, K L et al. (1998) Epitope specificity of CD44 for monoclonal antibody-dependent facilitation of marrow engraftment in a canine model. Blood 91:3494-502
Krizanac-Bengez, L; Moore, P F; Barsoukov, A et al. (1998) The expression and differentiation pattern of cell antigens and adhesion molecules on the nonadherent cell population in canine long-term marrow culture: a biphasic development of myeloid and lymphoid cells. Tissue Antigens 51:141-55
Sandmaier, B M; Storb, R; Santos, E B et al. (1996) Allogeneic transplant of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors. Blood 87:3508-13
Rossbach, H C; Krizanac-Bengez, L; Santos, E B et al. (1996) An antibody to CD44 enhances hematopoiesis in long-term marrow cultures. Exp Hematol 24:221-7
Sandmaier, B M; Storb, R; Liu, Y et al. (1996) An anti-CD44 antibody does not enhance engraftment of DLA-identical marrow after low-dose total body irradiation. Transpl Immunol 4:271-4
Tan, P H; Liu, Y; Santos, E B et al. (1995) Mechanisms of enhancement of natural killer activity by an antibody to CD44: increase in conjugate formation and release of tumor necrosis factor alpha. Cell Immunol 164:255-64
Tan, P H; Sandmaier, B M; Stayton, P S (1995) Characterization of an anti-CD44 single-chain FV antibody that stimulates natural killer cell activity and induces TNF alpha release. Immunol Invest 24:907-26
Tan, P H; Santos, E B; Rossbach, H C et al. (1993) Enhancement of natural killer activity by an antibody to CD44. J Immunol 150:812-20
Greinix, H T; Storb, R; Bartelmez, S H (1992) Specific growth inhibition of primitive hematopoietic progenitor cells mediated through monoclonal antibody binding to major histocompatibility class II molecules. Blood 80:1950-6
Greinix, H T; Ladiges, W C; Graham, T C et al. (1991) Late failure of autologous marrow grafts in lethally irradiated dogs given anti-class II monoclonal antibody. Blood 78:2131-8